SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid community excitement and anticipation of a breakout, with many members expressing bullish sentiment using terms like "WAGMI" (We're All Gonna Make It). Some traders are eyeing a potential short squeeze, while others focus on the broader potential of the Solana ecosystem, including meme coins. There are those, however, who are concerned about potential dumps.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its core belief in decentralized systems and a shared vision of financial freedom on the Solana network, which is captured in its ticker name. Community members are actively sharing positive sentiment and emphasizing the project's resilience, long-term potential, and strong community, viewing it as more than just a meme coin. The discussion highlights the potential for significant growth and a strong belief in the future of Web3.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid renewed interest in meme stocks, sparked by a White House social media post referencing the company. The community is actively discussing potential short squeezes and reminiscing about the stock's 2021 surge, with some drawing comparisons to other trending stocks.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to renewed trading momentum and discussions around its low float, with some traders speculating about a potential short squeeze. The company's recent earnings report, highlighting strong revenue growth but a net loss, is also a key point of discussion. Community members are actively debating potential price movements and trading strategies, with some expressing caution about its volatility.

Pump.fun

$PUMP is trending as the community rallies around the "We're All Gonna Make It" ($WAGMI) narrative, emphasizing community support and long-term goals. Some users highlight the upcoming 6-month milestone and growing mindshare, while others discuss potential for significant gains within the Solana meme coin ecosystem.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with many hoping for a "triple beat" and positive guidance. The community is also closely watching for potential rate cuts and any news regarding S&P 500 inclusion. Optimism is high, with some predicting a significant price surge if key resistance levels are broken.

Smart Logistics Global Ltd. operates as a business-to-business contract logistics provider, specializing in industrial raw materials line-haul transportation. The company develops a smart logistics digital ecosystem for road transport by leveraging innovation, digital analytics, and infrastructure development. It enhances supply chain efficiency, shortens transit times, and improves client visibility using its integrated platform. Its services cater to a diverse range of industries including manufacturing, construction, and FMCG (Fast-Moving Consumer Goods), enabling seamless and cost-effective movement of goods across regional and national networks. The company was founded by Kwok Chiu Hue on October 8, 2020 and is headquartered in Hong Kong.

Smart Logistics Global Ltd.

Smart Logistics Global Limited Ordinary Shares

SLGB is trending due to its volatile price action and recent IPO status, with traders actively discussing potential short squeezes and price targets. Community members are also comparing it to other low-float Chinese stocks that have experienced significant gains, while some express concerns about potential manipulation. The stock's low float and recent price swings are key discussion points.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp ($UAMY) is trending due to overnight price movement potentially linked to discussions surrounding a deal with Larvotto Resources (LRV). The community is debating whether a deal is still viable after an initial rejection, with some speculating about government intervention and the potential for dilution. Broader concerns about rare earth element trade with China are also fueling the conversation, though UAMY focuses on antimony, a critical mineral, and some see this as an overreaction to a China REE trade truce.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as discussions focus on its AI capabilities and recent partnerships with major players like Google and Qatar Airways. The community is weighing its growth potential in the BNPL sector against concerns about the broader economic climate and the stock's performance since its IPO. Some investors view Klarna as undervalued, particularly compared to competitors, while others express caution regarding its business model and potential for market volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as community members discuss a recently announced $150M registered direct offering and its implications for the company's growth.  Many view the raise as a bullish signal indicating potential expansion and anticipation of increasing purchase orders, especially given the demand in AI, while some express concerns about dilution. Community members are highlighting POET's technology, suggesting potential acquisitions and significant moves in the near future.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why

Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

​Retail interest for Phathom Pharmaceuticals soared on Thursday after the company reported first-quarter results, unveiled a sweeping cost-reduction plan and reaffirmed its target to achieve operational profitability by 2026.The company posted Q1 revenue of $28.5 million, slightly below the $29.02 million consensus.&nbsp;Its net loss widened to $94.3 million from $82.9 million a year earlier, driven largely by increased advertising and promotional spend for its lead drug, VOQUEZNA.“2025 will be an inflection point for Phathom,” said CEO Steve Basta.&nbsp;The company announced a 6% workforce reduction, multiple leadership changes, and significant cuts in external spending.&nbsp;Phathom expects the moves to reduce 2025 operating expenses by $60 million to $70 million and lower quarterly spend to under $55 million by the fourth quarter.Basta said the company’s actions are designed to support long-term growth without raising new equity or debt. He added that sales force strength remains a top priority, with commercial personnel now comprising around 75% of the total workforce.Voquezna prescriptions rose 8% sequentially in Q1 to 127,000, while cumulative prescriptions surpassed 390,000 as of April 18.&nbsp;Commercial access remained strong, with coverage extending to over 120 million lives, including more than 80% of commercially insured patients.Phathom also paused its planned Phase 2 trial for eosinophilic esophagitis and is awaiting an FDA decision on its citizen petition seeking full NCE exclusivity through 2032.Retail traders on Stocktwits remained optimistic despite the revenue miss, with sentiment marked as ‘bullish’ amid a 900% surge in 24-hour messaging volume.&nbsp;Several users said they were buying the dip, expressing continued confidence in the company’s long-term prospects.<stembedurl>https://stocktwits.com/DrDare/message/613236534</stembedurl>One user said the volume spike was notable but still lower than on days when major patent or executive updates had occurred.&nbsp;<stembedurl>https://stocktwits.com/Morrito23/message/613282417</stembedurl>They noted persistent concerns over cash burn, but said they welcomed management's move to finally address the issue publicly.Some traders described the first quarter as unusually difficult for pharmaceutical firms, citing formulary changes and deductible resets.&nbsp;Others saw the update as a turning point, with one saying the stock could become a buyout candidate if exclusivity concerns are resolved and revenue momentum continues.<stembedurl>https://stocktwits.com/Canvasback33/message/613238887</stembedurl>Shares of Phanthom have fallen 54.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Packaging and pills of different types of psychotropic medications are seen in this illustration photo taken in Warsaw, Poland on 22 April, 2025. (Photo by Jaap Arriens/NurPhoto via Getty Images)

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 

Equity

Phathom's Voquezna prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 


2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAT News

PHATPhathom Pharmaceuticals Inc